Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.19

-3.7%

11:52 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jj_ who wrote (4305)	7/26/2001 1:00:00 AM
From: jj_	Read Replies (1) of 52153

dallasnews.com Wednesday \| July 25, 2001 Genetically engineered drug promising against leukemia 07/26/2001 Associated Press BOSTON – A genetically engineered drug shows great early promise in tracking down and killing a rare leukemia, raising doctors' hopes in the long quest for a magic bullet against cancer. Eleven of the 16 patients treated in a study of the drug were left with no readily detectable trace of the disease. The experimental drug relies on a piece of antibody from a mouse's immune system to latch onto the cancer cells while shunning normal cells. A bacterial poison fused to the antibody is carried inside the cancer cells and kills them. Doctors have long tested mouse antibodies as drugs. Researchers said this drug and similar ones may eventually prove useful for other types of cancer. Researchers at the National Cancer Institute in Bethesda, Md., developed and tested the drug, a so-called immunotoxin known as BL22, on 16 patients with hairy cell leukemia untreatable by the usual chemotherapy. Their study appears in Thursday's edition of The New England Journal of Medicine.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next